STAAR Surgical Full Year 2024 Earnings: Misses Expectations

Simply Wall St

February 27, 2025

STAAR Surgical (NASDAQ:STAA) Full Year 2024 Results

Key Financial Results

Revenue: US$313.9m (down 2.6% from FY 2023).
Net loss: US$20.2m (down by 195% from US$21.3m profit in FY 2023).
US$0.41 loss per share (down from US$0.44 profit in FY 2023).

revenue-and-expenses-breakdown — NasdaqGM:STAA Revenue and Expenses Breakdown February 27th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

STAAR Surgical Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 8.4%. Earnings per share (EPS) was also behind analyst expectations.

The primary driver behind last 12 months revenue was the China segment contributing a total revenue of US$161.3m (51% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to US$108.3m (42% of total expenses). Explore how STAA's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 3.8% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of STAAR Surgical's balance sheet and an in-depth analysis of the company's financial position.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.